Introduction
In recent years Gram positive bacteria have re-emerged as important pathogens, both in the community and hospital. To compound the problems, antimicrobial resistance, long considered the domain of Gram negative bacteria, is being increasingly exhibited by Gram positive strains.
This short review will look at renewed interest in previously uncommon pathogens "our old friends"-Corynebacterium diphtheriae and Streptococcus pyogenes; and the serious problems we face in treating patients infected with Staphylococcus aureus, Streptococcus pneumoniae and the enterococci.
Streptococcus pyogenes
Before the discovery of antibiotics, serious infections caused by S pyogenes were common and were responsible for as many as 50% of post-partum deaths and the major cause of deaths in patients with burns before World War II. ' The infectious sequelae, such as rheumatic fever, were also common. TMe introduction of penicillin resulted in the organism being consigned to the history books. But not for long.
Since the mid-1980s an increased incidence of invasive disease has been reported from many parts of the industrialised world, including the USA, the UK and Scandinavia.`4 Coincidentally, focal resurgence of rheumatic fever was reported in different areas in the USA, beginning in the Rocky Mountain area.5 6 The predominant serotypes associated with rheumatic fever were M 1, 3 Until recently, streptococcal isolates from cases of scarlet fever were only positive for SPE-B or SPE-C.9 Strains which produce SPE-A are now being isolated from patients with widespread cellulitis or necrotising fasciitis, associated with severe systemic toxicity, resembling staphylococcal toxic shock syndrome.'0 Strains isolated before 1940 were also positive for SPE-A; so it seems that the more toxic form of scarlet fever was prevalent prior to the introduction of antibiotics, and is now re-establishing itself.
The term streptococcal toxic shock-like syndrome (TSLS) has been used to describe patients with hypotension and multisystem failure typical of the staphylococcal disease."
This phenomenon can be partly explained by the fact that SPE-A shows 50% amino acid homology with staphylococcal enterotoxin B, one of the main toxins responsible for staphylococcal toxic shock syndrome.'2 The clinical outcome of TSLS depends on the interaction between the microbial virulence factors (M protein and SPEs) and the immune status of the host. 4 Penicillin remains the treatment of choice for streptococcal infection, but in patients with severe disease large numbers of the organisms can be found, and the efficacy of penicillin is thereby reduced. Two explanations have been proposed; the slower growth rate of streptococci when present in large numbers '3 The impact of penicillin resistance on the severity of disease has yet to be fully established. The main risk factors for infection by penicillin resistant pneumococci are similar to the risk factors for severe pneumococcal disease-extremes of age, hospitalisation, and previous antibiotic treatment.5' As initial empiric treatment is likely to be ineffective it is not surprising that the outcome in some patients is poor. However, a study from Barcelona has suggested that the mortality due to pneumococcal pneumonia is not affected by the penicillin susceptibility of the pneumococcus.5" Treatment of infections caused by penicillin resistant pneumococci has been reviewed elsewhere. 53 With intravenous treatment the concentrations of penicillin in the serum that can be achieved will greatly exceed the MIC of intermediately resistant and many fully resistant strains. Thus, a P-lactam remains the empiric drug of choice in this situation. However, if a highly resistant strain is suspected, vancomycin or a carbapenem should be considered. In the case of meningitis, penicillin is unlikely to be effective and the empiric therapy would be a third generation cephalosporin such as cefotaxime. Unfortunately There is also concern about disease caused by non-toxigenic C diphtheriae. The current status of C diphtheriae carriage in the UK is unknown. As clinical diphtheria is now so uncommon many microbiology laboratories no longer routinely look for the organism in throat swabs, and it is very possible that its isolation from other sites would be overlooked. Despite this, isolation of non-toxigenic strains of C diphtheriae has been more frequently reported.64 Increased pharyngeal carriage has been documented in homosexual men attending a genito-urinary clinic in London65 and in intravenous drug users.66 Invasive infection due to non-toxigenic C diphtheriae is well described, and typing has shown that clusters of infection have often been caused by single strains. 7 68 This would be a particular cause for concern if these strains were able to become toxin producers. Lysogenic conversion to toxin production is possible in vitro,69 but its clinical significance is unknown.
Conclusions
The resurgence of tese Gram positive organisms is unquestionable and resistance to multiple antimicrobial agents continues apace. We need to be aware of tese threats and hope that suitable alternatives to the classic or standard terapeutic agents are forthcoming.
